FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Washington, D	.C. 20549
---------------	-----------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number:	3235-0287							
	Estimated average burden								
l	hours per response:	0.5							

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

			or Section 30(n) of the investment Company Act of 1940			
1. Name and Address of Reporting Person* Parra Raul Jr.					tionship of Reporting Pers all applicable) Director Officer (give title	son(s) to Issuer 10% Owner Other (specify
(Last) (First) 1600 WEST MERIT PARKWAY		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/12/2024	X	below) CFO AND TREA	below)
			4. If Amendment, Date of Original Filed (Month/Day/Year)		idual or Joint/Group Filing	(Check Applicable
(Street) SOUTH JORDAN	UT	84095		Line) X	Form filed by One Report Form filed by More than Person	Ü
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication			
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						nat is intended to

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 2. Transaction 5. Amount of 1. Title of Security (Instr. 3) 2A. Deemed Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Securities Beneficially Owned Following Transaction Code (Instr. 8) Reported Transaction(s) (Instr. 3 and 4) (Instr. 4) (A) or (D) Code v Price ByCommon Stock, No Par Value 2,770 401(k) $Plan^{(1)}$ 03/12/2024 301 Common Stock, No Par Value S D \$74.52(2) 18,186 D Common Stock, No Par Value 03/12/2024 6,179 D \$73.92⁽³⁾ 12,007 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) S. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- qualified stock options (right to buy)	\$44.8							03/02/2019 ⁽⁴⁾	03/02/2025	Common Stock	4,000		4,000	D	
Non- qualified stock options (right to buy)	\$55.73							03/01/2020 ⁽⁵⁾	03/01/2026	Common Stock	30,000		30,000	D	
Non- qualified stock options (right to buy)	\$37.71							02/26/2021 ⁽⁶⁾	02/26/2027	Common Stock	10,722		10,722	D	
Non- qualified stock options (right to buy)	\$56.25							03/19/2022 ⁽⁷⁾	03/19/2028	Common Stock	9,681		9,681	D	
Non- qualified stock options (right to buy)	\$65.03							02/28/2023 ⁽⁸⁾	02/28/2029	Common Stock	14,570		14,570	D	
Non- qualified stock options (right to buy)	\$70.58							02/28/2024 ⁽⁹⁾	02/28/2030	Common Stock	13,576		13,576	D	

Explanation of Responses:

- 1. Represents plan holdings as of 03/12/2024.
- 2. The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$74.46 to \$74.56, inclusive. The reporting person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- 3. The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$73.50 to \$74.44, inclusive. The reporting person undertakes to provide to Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- 4. Becomes exercisable in equal annual installments of 20% commencing on 03/02/2019.
- 5. Becomes exercisable in equal annual installments of 20% commencing on 03/01/2020.
- $6. \ Becomes \ exercisable \ in \ equal \ annual \ installments \ of \ 25\% \ commencing \ on \ 02/26/2021.$
- 7. Becomes exercisable in equal annual installments of 25% commencing on 03/19/2022.
- $8. \ Becomes \ exercisable \ in \ equal \ annual \ installments \ of \ 25\% \ commencing \ on \ 02/28/2023.$
- 9. Becomes exercisable in equal annual installments of 25% commencing on 02/28/2024.

/s/ Brian G. Lloyd, Attorneyin-Fact 03/13/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.